Principal Financial Group Inc Biocryst Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

  • $167 Billion
  • Q1 2025

A detailed history of Principal Financial Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 16,495 shares of BCRX stock, worth $184,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,495
Previous 17,807 7.37%
Holding current value
$184,579
Previous $133,000 7.52%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 28, 2025
SELL
$7.06 - $9.39 $9,262 - $12,319
-1,312 Reduced 7.37%
16,495 $123,000
Q4 2024

Jan 31, 2025
BUY
$7.03 - $8.43 $125,183 - $150,113
17,807 New
17,807 $133,000
Q3 2024

Oct 31, 2024
BUY
$6.41 - $8.69 $2.41 Million - $3.27 Million
375,890 Added 1058.13%
411,414 $3.13 Million
Q2 2024

Jul 29, 2024
SELL
$4.13 - $6.79 $52,413 - $86,171
-12,691 Reduced 26.32%
35,524 $219,000
Q1 2024

Apr 29, 2024
BUY
$4.89 - $7.65 $1,056 - $1,652
216 Added 0.45%
48,215 $244,000
Q4 2023

Feb 07, 2024
SELL
$4.98 - $6.77 $3,381 - $4,596
-679 Reduced 1.39%
47,999 $287,000
Q3 2023

Nov 02, 2023
BUY
$6.71 - $7.92 $7,515 - $8,870
1,120 Added 2.36%
48,678 $344,000
Q2 2023

Aug 07, 2023
BUY
$6.96 - $8.81 $2,456 - $3,109
353 Added 0.75%
47,558 $334,000
Q1 2023

May 09, 2023
BUY
$7.94 - $11.84 $3,048 - $4,546
384 Added 0.82%
47,205 $393,000
Q4 2022

Feb 09, 2023
SELL
$10.5 - $14.2 $586,372 - $792,999
-55,845 Reduced 54.39%
46,821 $537,000
Q3 2022

Nov 09, 2022
SELL
$10.79 - $14.81 $1.04 Million - $1.43 Million
-96,743 Reduced 48.51%
102,666 $1.29 Million
Q2 2022

Aug 10, 2022
BUY
$7.89 - $17.88 $1.28 Million - $2.9 Million
162,417 Added 439.06%
199,409 $2.11 Million
Q1 2022

May 09, 2022
SELL
$11.56 - $19.76 $17,444 - $29,817
-1,509 Reduced 3.92%
36,992 $601,000
Q4 2021

Feb 09, 2022
SELL
$11.18 - $15.46 $167,834 - $232,085
-15,012 Reduced 28.05%
38,501 $534,000
Q3 2021

Nov 09, 2021
SELL
$14.21 - $17.65 $121,793 - $151,278
-8,571 Reduced 13.81%
53,513 $769,000
Q2 2021

Aug 10, 2021
SELL
$9.5 - $17.24 $101,241 - $183,726
-10,657 Reduced 14.65%
62,084 $981,000
Q1 2021

May 10, 2021
SELL
$7.37 - $13.61 $15,027 - $27,750
-2,039 Reduced 2.73%
72,741 $740,000
Q4 2020

Feb 08, 2021
BUY
$3.37 - $8.61 $66,779 - $170,615
19,816 Added 36.05%
74,780 $557,000
Q3 2020

Nov 06, 2020
SELL
$3.43 - $5.53 $5,947 - $9,589
-1,734 Reduced 3.06%
54,964 $189,000
Q2 2020

Aug 05, 2020
BUY
$1.9 - $5.61 $45,265 - $133,652
23,824 Added 72.47%
56,698 $270,000
Q1 2020

May 12, 2020
BUY
$1.6 - $4.11 $2,254 - $5,790
1,409 Added 4.48%
32,874 $66,000
Q4 2019

Feb 05, 2020
SELL
$1.59 - $3.45 $2,669 - $5,792
-1,679 Reduced 5.07%
31,465 $109,000
Q3 2019

Nov 13, 2019
BUY
$2.5 - $3.73 $8,477 - $12,648
3,391 Added 11.4%
33,144 $95,000
Q2 2019

Aug 12, 2019
SELL
$2.91 - $9.15 $3,736 - $11,748
-1,284 Reduced 4.14%
29,753 $113,000
Q1 2019

May 10, 2019
BUY
$7.38 - $9.72 $6,324 - $8,330
857 Added 2.84%
31,037 $253,000
Q4 2018

Feb 14, 2019
BUY
$6.51 - $9.6 $80,724 - $119,040
12,400 Added 69.74%
30,180 $244,000
Q3 2018

Nov 14, 2018
SELL
$5.52 - $7.99 $61,713 - $89,328
-11,180 Reduced 38.6%
17,780 $136,000
Q2 2018

Aug 13, 2018
BUY
$4.6 - $6.52 $6,817 - $9,662
1,482 Added 5.39%
28,960 $0
Q1 2018

May 14, 2018
BUY
$4.35 - $5.82 $9,939 - $13,298
2,285 Added 9.07%
27,478 $131,000
Q4 2017

Feb 13, 2018
BUY
$4.16 - $5.33 $54,720 - $70,110
13,154 Added 109.26%
25,193 $124,000
Q3 2017

Nov 02, 2017
BUY
$4.1 - $5.97 $49,359 - $71,872
12,039
12,039 $63,000

Others Institutions Holding BCRX

# of Institutions
293
Shares Held
177M
Call Options Held
721K
Put Options Held
489K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $2.08B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email